Adaptimmune Therapeutics PLC — Director's Dealing 2020

Dec 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-12-14

Reporting Person: Wood Gavin (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-14	Ordinary Shares with a nominal value of GBP0.001 per share	P	24000	$0.6896	Acquired	57000	Direct

Footnotes

F1: The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by Gavin Wood. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc.

F2: The 24,000 ordinary shares reported in Column 4 are represented by 4,000 ADSs.

F3: The price reported in Column 4 of $0.6896 per ordinary share is derived from the purchase price paid on December 14, 2020 of $4.1375 per ADS divided by six.

F4: The 57,000 ordinary shares reported in Column 5 include 33,000 ordinary shares represented by 5,500 ADSs owned by Mr. Wood prior to the purchase reported in Column 4. These shares are held in the form of ADSs by Mr. Wood.